Details for New Drug Application (NDA): 022160

NDA 022160 describes OXALIPLATIN, which is a drug marketed by Accord Hlthcare, Actavis, Actavis Totowa, Am Regent, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Oncol, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hengrui Pharma, Hospira Inc, Hospira Worldwide, Meitheal, Mylan Labs Ltd, Norvium Bioscience, Novast Labs, Qilu Pharm Hainan, Sandoz, Sun Pharm, and Teva Pharms, and is included in twenty-seven NDAs. It is available from eighteen suppliers. Additional details are available on the OXALIPLATIN profile page.

The generic ingredient in OXALIPLATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.

Summary for 022160

Tradename:	OXALIPLATIN
Applicant:	Teva Pharms
Ingredient:	oxaliplatin
Patents:	0

Pharmacology for NDA: 022160

Suppliers and Packaging for NDA: 022160

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	022160	NDA	Teva Parenteral Medicines, Inc.	0703-3985	0703-3985-01	1 VIAL, SINGLE-USE in 1 CARTON (0703-3985-01) / 10 mL in 1 VIAL, SINGLE-USE
OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	022160	NDA	Teva Parenteral Medicines, Inc.	0703-3986	0703-3986-01	1 VIAL, SINGLE-USE in 1 CARTON (0703-3986-01) / 20 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	50MG/10ML (5MG/ML)
Approval Date:	Aug 7, 2009	TE:	AP	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	100MG/20ML (5MG/ML)
Approval Date:	Aug 7, 2009	TE:	AP	RLD:	Yes

Complete Access Available with Subscription